Medicus Sciences Acquisition Warned of Nasdaq Delisting, Opts to Liquidate

Medicus Sciences Acquisition in an 8-K filing said it received a Nasdaq notice that it faces delisting for failure to hold an annual meeting of shareholders within the required timeline.

Because it is unlikely Medicus will be able to complete a business combination before its Feb. 18 completion deadline, SPAC in the filing said it intends to liquidate after the deadline.

The SPAC raised $92 million in a February 2021 IPO to focus on the medical technology sector, both in the United States and internationally.

Medicus almost a year ago called off merger talks with Anteris Technology, an Australia-based medical tech company focused on structural heart components, including heart valves. Read more.

Total
0
Shares
Related Posts
Read More

AGBA Waives Lock-Up Period for TAG Deal

After facing a Nasdaq delisting earlier this summer, the exchange in June agreed to give AGBA until November to complete a deal. A Nasdaq rule requires SPACs to close a deal within 36 months of their IPO, which in AGBA’s case was back in May 2019.